What is it about?
This study explores the anticancer potential of natural compounds found in pomegranate (Punica granatum). Using molecular docking, we investigated how ellagic acid, punicallin, and punicalagin interact with TRIM24, a protein associated with cancer progression. Their binding affinities were compared with the anticancer drugs methotrexate and doxorubicin. The results showed that punicalagin had the strongest predicted binding to TRIM24, highlighting its potential for further investigation as a natural anticancer candidate.
Featured Image
Photo by Tal Surasky on Unsplash
Why is it important?
This research is important because there is a continuing need for safer and more effective approaches to cancer treatment. Our findings show that pomegranate-derived metabolites, particularly punicalagin and punicallin, have promising predicted interactions with TRIM24, a protein associated with cancer progression. Their strong binding compared with the reference anticancer drugs highlights their potential as candidates for further anticancer research and drug development. Further laboratory and in vivo studies are needed to confirm their effectiveness and safety.
Perspectives
The findings of this study provide a computational basis for further investigation of pomegranate-derived metabolites as potential anticancer candidates. In particular, punicalagin and punicallin showed promising binding interactions with the TRIM24 PHD-bromodomain. Future research should focus on experimental validation through in vitro and in vivo studies to confirm their anticancer activity, safety, and therapeutic potential. Further investigation may also help clarify their molecular mechanisms and support the development of novel plant-derived approaches for cancer therapy.
Mr. Deepak Pravin Gavate
Read the Original
This page is a summary of: Docking Studies of Punica granatum Metabolites: A Pathway toward Novel
Anti-Cancer Therapeutics, Drug Metabolism and Bioanalysis, April 2026, Bentham Science Publishers,
DOI: 10.2174/0118723128370081250407102015.
You can read the full text:
Resources
Published Research Article – Docking Studies of Punica granatum Metabolites
This is the published research article exploring the molecular docking of Punica granatum metabolites with the TRIM24 PHD-bromodomain and comparing their predicted binding affinities with conventional anticancer drugs.
Deepak P. Gavate
My ORCID profile provides an overview of my academic and research background in Pharmaceutical Chemistry, including my research interests in medicinal chemistry, drug discovery, molecular docking, organic synthesis, phytochemical research, and pharmaceutical research. It also includes my academic employment and published research work, including the study “Docking Studies of Punica granatum Metabolites: A Pathway toward Novel Anti-Cancer Therapeutics.”
Contributors
The following have contributed to this page
